Product nameAnti-IRF5 antibody
See all IRF5 primary antibodies
DescriptionRabbit polyclonal to IRF5
Tested applicationsSuitable for: IP, WBmore details
Species reactivityReacts with: Mouse
Predicted to work with: Human
Synthetic peptide within Mouse IRF5 aa 175-225. The exact sequence is proprietary.
Database link: P56477
- WB: Mouse bone marrow dendritic cell lysate. IP: Mouse bone marrow dendritic cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab245475 was affinity purified using an epitope specific to IRF5 immobilized on solid support.
- Epigenetics and Nuclear Signaling
- Domain Families
- HLH / Leucine Zipper
Our Abpromise guarantee covers the use of ab245475 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2-10 µg/mg of lysate.|
|WB||1/200 - 1/10000. Predicted molecular weight: 56 kDa.|
Involvement in diseaseGenetic variations in IRF5 are associated with susceptibility to inflammatory bowel disease type 14 (IBD14) [MIM:612245]. IBD14 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
Genetic variations in IRF5 are associated with susceptibility to systemic lupus erythematosus type 10 (SLEB10) [MIM:612251]. Systemic lupus erythematosus (SLE) is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. It is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Genetic variations in IRF5 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.
Sequence similaritiesBelongs to the IRF family.
Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
- Information by UniProt
- Interferon regulatory factor 5 antibody
- Interferon regulatory factor 5 bone marrow variant antibody
- IRF 5 antibody
IRF5 was immunoprecipitated from 1 mg (20% of IP loaded) mouse bone marrow dendritic cell lysate using ab245475 at 6 µg/mg lysate. Western blot was performed on the immunoprecipitate using ab245475 at 1 µg/ml.
Lane 1: ab245475 IP in mouse bone marrow dendritic cell lysate.
Lane 2: Control IgG in mouse bone marrow dendritic cell lysate.
Detection: Chemiluminescence with an exposure time of 30 seconds.
All lanes : Anti-IRF5 antibody (ab245475) at 0.04 µg/ml
Lane 1 : Mouse bone marrow dendritic cell lysate at 50 µg
Lane 2 : Mouse bone marrow dendritic cell lysate at 15 µg
Developed using the ECL technique.
Predicted band size: 56 kDa
Exposure time: 3 minutes
ab245475 has not yet been referenced specifically in any publications.